Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asperger Disorder Clear all
Active, not recruiting No phase listed Observational

Phenotypic and Genetic Factors in Autism Spectrum Disorders

NCT00910559
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism

NCT00211783
View directory record Official record
Conditions
Autism, Asperger's Syndrome
Interventions
fMRI
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 20, 2026, 5:09 AM EDT
Not listed Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925
View directory record Official record
Conditions
Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
Interventions
Gammaplex 5%
Drug
Lead sponsor
Isaac Melamed
Industry
Eligibility
4 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents with Autism Spectrum Disorders

NCT01361503
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD)

NCT05176808
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Active Autistic Disorder, Autism, Asperger Syndrome, PDD-NOS, Social Communication Delay, Mixed Expressive Receptive Language Disorder, Other Symbolic Dysfunctions
Interventions
Early Achievements- Parent Coaching Intervention
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Months to 42 Months
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional

Cholesterol in ASD: Characterization and Treatment

NCT00965068
View directory record Official record
Conditions
Autism, Asperger Disorder, PDD-NOS
Interventions
Cholesterol
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders

NCT02836405
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 20, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Diffusion Tensor Imaging in Autism

NCT00382382
View directory record Official record
Conditions
Autistic Disorder
Interventions
diffusion tensor imaging (DTI)
Other
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 12 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

NCT00080145
View directory record Official record
Conditions
Child Development Disorders, Pervasive
Interventions
Risperidone, Behavior Therapy
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 13 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 20, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational

Genetic Contributions to Autism Spectrum Disorders

NCT01160783
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Asperger's Syndrome, Pervasive Developmental Disorder
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Recruiting No phase listed Observational

SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

NCT03222375
View directory record Official record
Conditions
Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Neurodevelopmental Disorders, Mental Disorders, Asperger's Syndrome, Neurobehavioral Manifestations, Nervous System Diseases
Interventions
SQUED™ series 28.1 home-use
Device
Lead sponsor
American Federation of Medical Synergetics
Other
Eligibility
1 Month to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Salivary miRNA Diagnostic Test for Autism

NCT02832557
View directory record Official record
Conditions
Autism Spectrum Disorder, Developmental Delay
Interventions
Salivary collection, Vineland Adaptive Behavior Scale-III Assessment, Medical history questionaire, Autism Diagnostic Observation Schedule -2nd edition (ADOS-2), Mullen Scales of Early Learning
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
24 Months to 48 Months
Enrollment
998 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational

Predictors of Caregiver Adaptation to Pervasive Developmental Disorders

NCT00496210
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Rett's Disorder
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 20, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

NCT01706523
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
STX209 (arbaclofen)
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety

NCT01919970
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder, Specific Phobia
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

NCT00251303
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational

Pediatric Patients With Metabolic or Other Genetic Disorders

NCT02769949
View directory record Official record
Conditions
Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome, Developmental Delay
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavior Therapy for Irritability in Autism

NCT04654260
View directory record Official record
Conditions
Autism Spectrum Disorder, Irritability, Disruptive Behavior, Anger, Aggression, Asperger Syndrome, Pervasive Developmental Disorder
Interventions
Behavioral Therapy for Irritability in Autism, Psychoeducation and Supportive Therapy (PST)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

NCT01337687
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

NCT01288716
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Arbaclofen
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 20, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 20, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

A Folinic Acid Intervention for Autism Spectrum Disorders

NCT01602016
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions
Folinic Acid and placebo, Folinic Acid
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
3 Years to 14 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 20, 2026, 5:09 AM EDT
Completed No phase listed Observational

Advanced Grandparental Age as a Risk Factor for Autism

NCT00464477
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Rett Syndrome
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Sep 20, 2026, 5:09 AM EDT